PRINCETON, N.J. and LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and AstraZeneca (NYS: AZN) today announced that the European Commission has approved Forxiga ™ (dapagliflozin) ...

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...

AstraZeneca PLC AZN announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending the marketing approval for ...

AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU).

The company said it has received an Import and Market permission in Form CT-20 (Subsequent New Drug Approval) from the Central Drugs Standard Control Organisation, Directorate General of Health ...

Add Yahoo as a preferred source to see more of our stories on Google. Forxiga tablets are indicated as a once-daily oral medication to improve glycaemic control in adult patients with type 2 diabetes.

Forxiga, a once-daily oral agent, provides physicians with a new option to improve glycaemic control as monotherapy in metformin-intolerant patients or combination therapy Reduction of weight and ...